Article info
PDFClinical trial
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
- Correspondence to Dr Osnat Elyashiv, University College CRUK and UCL Cancer Trials Centre, UCL Cancer Institute, London WC1E 6DD, UK; osnatelyashiv{at}gmail.com
Citation
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Publication history
- Accepted October 6, 2020
- First published October 23, 2020.
Online issue publication
February 28, 2022
Article Versions
- Previous version (4 January 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.